Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
V
308080
vs
K
KOSPI 200
Over the past 12 months, ViGenCell Inc has underperformed KOSPI 200, delivering a return of +71% compared to KOSPI 200's +119% growth.
Stocks Performance
308080 vs KOSPI 200
Performance Gap
308080 vs KOSPI 200
Performance By Year
308080 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ViGenCell Inc
Glance View
ViGenCell Inc is a South Korean cell therapy company. It develops and sells living-cell medicines used to treat hard-to-fix diseases, especially in areas like tissue repair, immune disorders, and other conditions where standard drugs do not work well. Its main customers are hospitals, clinics, and other healthcare partners that use these therapies in patient care or clinical programs. The company makes money by selling its cell therapy products and by doing related research and development work with medical or pharmaceutical partners. In this business, value comes from moving cells from the lab into a controlled medical product that doctors can use. That means ViGenCell has to handle cell processing, quality control, and the regulatory work needed to turn biology into a usable treatment. What makes the company different is its role in the healthcare supply chain: it is not a traditional drug maker that sells pills or injections in bulk, but a developer of personalized or cell-based medicines. That makes its business more tied to specialized manufacturing, clinical know-how, and partnerships with medical institutions than to mass-market consumer sales.